石药集团(01093.HK)与倍而达药业订立产品授权及商业化协议
格隆汇 3 月 9日丨石药集团(01093.HK)公告,公司全资附属公司石药(上海)有限公司("石药上海")已与上海倍而达药业有限公司("倍而达药业")订立产品授权及商业化协议,内容有关其产品BPI-7711胶囊(用于治疗非小细胞肺癌不可逆的第三代小分子表皮生长因子受体酪氨酸激酶抑制剂(EGFR—TKI))独家产品授权及商业化。
根据该协议,石药上海将获得BPI-7711胶囊独家权利,以于中华人民共和国(包括香港特别行政区和澳门特别行政区,但不包括台湾地区)进行BPI-7711胶囊的商业化活动,并拥有BPI-1178胶囊(CDK4/6抑制剂)商业化授权的优先谈判权。
与此同时,集团同意向倍而达药业方面进行股权认购,首次认购金额人民币2亿元,须待若干先决条件获达成后方可作实。
BPI-7711胶囊将于近期在中国提交产品上市申请。
董事会相信,该产品的引入将进一步丰富集团肿瘤产品线。集团强大的销售及推广能力,将加速推动该产品的商业化,满足中国患者迫切的临床需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.